Last reviewed · How we verify
GenHevac B Pasteur
GenHevac B Pasteur is a recombinant hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen.
GenHevac B Pasteur is a recombinant hepatitis B vaccine that stimulates the immune system to produce antibodies against hepatitis B surface antigen. Used for Prevention of hepatitis B infection in adults and children.
At a glance
| Generic name | GenHevac B Pasteur |
|---|---|
| Also known as | Sanofi Pasteur MSD |
| Sponsor | ANRS, Emerging Infectious Diseases |
| Drug class | Recombinant vaccine |
| Target | Hepatitis B surface antigen (HBsAg) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains recombinant hepatitis B surface antigen (HBsAg) produced in yeast cells, which triggers both humoral and cellular immune responses. This leads to the production of protective antibodies (anti-HBs) and memory B cells that provide long-term immunity against hepatitis B virus infection.
Approved indications
- Prevention of hepatitis B infection in adults and children
Common side effects
- Injection site pain or swelling
- Fever
- Fatigue
- Headache
Key clinical trials
- Low Grade Lymphoma (PHASE4)
- Trial Comparing Two Strategies of Vaccination Against Hepatitis B in HIV-infected Patients Non Responding to Primary Immunization (B-BOOST) (PHASE3)
- Trial Comparing Three Strategies of Vaccination Against the Virus of Hepatitis B in HIV Infected Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GenHevac B Pasteur CI brief — competitive landscape report
- GenHevac B Pasteur updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI